Skip to main content

ADVERTISEMENT

precision medicine

Research Reports
12/13/2023
Simon R. Davies, MBBCh, MD
Kathleen Lyons, MBBCh
Kausik Mukherjee, MBBS
Ramakrishna Kishore, MBBS
Khurram Hashmi, MBBCh
Maria Dyban, LLM
Anna Kuczynska, MBBCh
Simon R. Davies, MBBCh, and colleagues investigate the impact of HealthPathways on management and primary care clinicians in a musculoskeletal radiology department.
Simon R. Davies, MBBCh, and colleagues investigate the impact of HealthPathways on management and primary care clinicians in a musculoskeletal radiology department.
Simon R. Davies, MBBCh, and...
12/13/2023
Journal of Clinical Pathways
Research Reports
09/19/2023
Julie Wiedower, PhDc
Nicole Zhang, MPH
Rebecca Nagy, MS
Kathryn Lang, MD
Jayati Saha, PhD, MPH
Julie Wiedower, PhDc, and colleagues analyze the frequency of real-world off-label therapy utilization post–comprehensive genomic profiling via liquid biopsy in precision oncology.
Julie Wiedower, PhDc, and colleagues analyze the frequency of real-world off-label therapy utilization post–comprehensive genomic profiling via liquid biopsy in precision oncology.
Julie Wiedower, PhDc, and...
09/19/2023
Journal of Clinical Pathways
OCPC: IN SESSION
09/19/2023
Matthew Biancalana, PhD
Tushar Pandey, MBA
Mathew Biancalana, PhD, and Tushar Pandey, MBA, discuss how artificial intelligence can enhance the field of precision medicine and help unburden physicians from laborious and repetitive tasks in diagnostic analyses.
Mathew Biancalana, PhD, and Tushar Pandey, MBA, discuss how artificial intelligence can enhance the field of precision medicine and help unburden physicians from laborious and repetitive tasks in diagnostic analyses.
Mathew Biancalana, PhD, and...
09/19/2023
Journal of Clinical Pathways
Review
09/19/2023
Winston Wong, PharmD
Gordon Kuntz
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon Kuntz provide an update on the current status of the research and barriers for using next-generation sequencing in NSCLC and summarize the discussion and next steps that the NGS Institute’s NSCLC Subcommittee...
Winston Wong, PharmD, and Gordon...
09/19/2023
Journal of Clinical Pathways
News
07/09/2020
A new study published in The Oncologist (online July 6, 2020; doi:10.1634/theoncologist.2019-0864) demonstrated the clinical utility of companion diagnostic testing as a first step in treating non-squamous advanced...
A new study published in The Oncologist (online July 6, 2020; doi:10.1634/theoncologist.2019-0864) demonstrated the clinical utility of companion diagnostic testing as a first step in treating non-squamous advanced...
A new...
07/09/2020
Journal of Clinical Pathways
News
06/08/2020
Next-generation sequencing (NGS) has the potential to directly impact treatment decisions and outcomes in patients with acute myeloid leukemia (AML), according to a study presented at the American Society of Clinical...
Next-generation sequencing (NGS) has the potential to directly impact treatment decisions and outcomes in patients with acute myeloid leukemia (AML), according to a study presented at the American Society of Clinical...
...
06/08/2020
Journal of Clinical Pathways
Research in Review
08/15/2017
JCP Editors
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts. Mutations within the SPOP gene are the most frequently documented genetic changes in...
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts. Mutations within the SPOP gene are the most frequently documented genetic changes in...
Recent...
08/15/2017
Journal of Clinical Pathways
Interview
08/03/2017
JCP Editors
Journal of Clinical Pathways spoke with Aymen Elfiky, MD, MPH, MSc, attending physician, clinical oncology, Dana Farber Cancer Institute (Boston, MA), about clinical pathway implementation at the Institute,...
Journal of Clinical Pathways spoke with Aymen Elfiky, MD, MPH, MSc, attending physician, clinical oncology, Dana Farber Cancer Institute (Boston, MA), about clinical pathway implementation at the Institute,...
...
08/03/2017
Journal of Clinical Pathways
Research in Review
06/13/2017
JCP Editors
Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...
Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...
...
06/13/2017
Journal of Clinical Pathways
Research in Review
06/13/2017
JCP Editors
Current National Comprehensive Cancer Network (NCCN) guidelines and Gleason scores cannot reliably stratify patients with risk of prostate cancer for the presence or absence of pathogenic germline variants,...
Current National Comprehensive Cancer Network (NCCN) guidelines and Gleason scores cannot reliably stratify patients with risk of prostate cancer for the presence or absence of pathogenic germline variants,...
...
06/13/2017
Journal of Clinical Pathways